Research Project

Project Title:	Obinutuzumab in Primary MN (ORION)
Project Type:	Clinical Trial, Enrolment ongoing
Disease group(s):	Immune glomerulopathies
Project Summary:	Obinutuzumab is a humanized monoclonal antibody with enhanced B cell-depleting potential. Due to humanization and glycoengineering, this drug may be safe and effective in inducing disease remission even in patients with prior hypersensitivity reactions to rituximab. Moreover, it has been found to be effective in patients with membranous nephropathy who failed to respond to rituximab.
Lead principal investigator(s):	Piero Ruggenenti, Bergamo
Co-investigator(s):	Laura Cappelletti, Bergamo Alessia Gennarini, Bergamo Livia Maria Surdi, Bergamo
Project Period:	02/2022 - 04/2025